HSPA5 and prostate cancer: Subsequent studies by Arap et al. demonstrated that synthetic chimeric peptides designed from GRP78 binding motifs (i.e., WIFPWIQL and WDLAWMFRLPVG), fused to the programmed cell death-inducing sequence, can decrease tumor progression in preclinical models of breast and prostate cancer [115].